Genmab A/S (GNMSF) EBITDA Margin (2018 - 2026)
Genmab A's (GNMSF) quarterly EBITDA Margin came in at 20.09% in Q1 2026, down 620.0% YoY from 3.86% in Q1 2025, and down 46.89% on a QoQ basis from 37.83% in Q3 2025.
Genmab A/S (GNMSF) EBITDA Margin (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 5 years of EBITDA Margin data on file, last reported at 20.09% in Q1 2026.
- Quarterly EBITDA Margin fell 620.0% year-over-year to 20.09% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32.52% (up 561.0% YoY) and the FY2025 annual result came in at 28.63%, down 251.0% from the prior year.
- EBITDA Margin slipped to 20.09% in Q1 2026, from 37.83% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 37.83% in Q3 2025 to a low of 19.24% in Q1 2024.
- A 3-year average of 27.49% and a median of 26.29% in 2025 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2025 — EBITDA Margin surged 794 bps — and 2026, when it sank 620 bps.
- Tracing GNMSF's EBITDA Margin over 3 years: stood at 30.12% in 2024, then rose by 26 bps to 37.83% in 2025, then plunged by 47 bps to 20.09% in 2026.
- The last three EBITDA Margin figures came in at 20.09% (Q1 2026), 37.83% (Q3 2025), and 33.41% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 32.47% |
| Mar 31, 2026 | 20.09% |
| Sep 30, 2025 | 37.83% |
| Jun 30, 2025 | 33.41% |
| Mar 31, 2025 | 26.29% |
| Sep 30, 2024 | 30.12% |
| Jun 30, 2024 | 25.47% |
| Mar 31, 2024 | 19.24% |
| Dec 31, 2019 | 0.00% |
| Sep 30, 2019 | 67,248,452,652,513.27% |
| Dec 31, 2018 | 38.52% |